Trenkwalder C
Ludwig Maximilian University, Munich, Germany.
Clin Neurosci. 1998;5(2):107-14.
The frequency of sleep complaints in patients with Parkinson's disease (PD) is estimated to be between 60-90% and a variety of either disease-related or secondary mechanisms and the dopaminergic treatment itself contributes to the development of different sleep disturbances. These comprise slight, fragmented sleep with increased number of arousals and awakenings, and PD-specific motor phenomena such as nocturnal immobility, rest tremor, eye-blinking, dyskinesias, and other phenomena such as periodic and nonperiodic limb movements in sleep, restless legs syndrome, fragmentary myoclonus, and respiratory dysfunction in sleep. Depression and hallucinations/psychosis further complicate the picture. The incidence of REM sleep behavior disorder (RBD) with nightmares and violent behavior is increased in PD and may occur as a preclinical disease-related symptom. A careful sleep history of patients and their partners, polysomnograms when necessary, motor and psychiatric assessments should precede individual treatment strategies, which include adjusting dopaminergic daytime treatment, benzodiazepines for RBD, reduction of anticholinergic drugs, and, if necessary, clozapine for nocturnal psychosis.
据估计,帕金森病(PD)患者睡眠障碍的发生率在60%-90%之间,多种与疾病相关或继发的机制以及多巴胺能治疗本身都促使不同睡眠障碍的发生。这些睡眠障碍包括轻微的、碎片化的睡眠,觉醒和醒来次数增加,以及特定于PD的运动现象,如夜间不动、静止性震颤、眨眼、运动障碍,还有其他现象,如睡眠中的周期性和非周期性肢体运动、不宁腿综合征、片段性肌阵挛以及睡眠呼吸功能障碍。抑郁和幻觉/精神病会使情况更加复杂。伴有噩梦和暴力行为的快速眼动睡眠行为障碍(RBD)在PD患者中的发生率增加,且可能作为临床前与疾病相关的症状出现。在制定个体化治疗策略之前,应仔细询问患者及其伴侣的睡眠史,必要时进行多导睡眠图检查、运动和精神评估,个体化治疗策略包括调整日间多巴胺能治疗、使用苯二氮䓬类药物治疗RBD、减少抗胆碱能药物,如果有必要,使用氯氮平治疗夜间精神病。